A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
The final of the 'Big 6' energy firms to cut prices - EDF - has announced it is reducing gas tariffs by just 1.3%.
Memorial and Learning Centre to use digital technology to commemorate and educate about the Holocaust
ITV News returns to Bergen-Belsen with Bernard Levy, a Jewish British army officer who was only 19 years old when he liberated the camp.